Results 181 to 190 of about 230,395 (312)

Invariant Natural Killer T Cells in Cancer Immunotherapy: Lipid-Based Modulation, Nanotechnology, and Translational Advances. [PDF]

Int J Mol Sci
Aloliqi AA, Alnuqaydan AM, Alshebremi M, Khan A, Khan MA.   +4 more
europepmc   +1 more source

Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis. [PDF]

Front Immunol, 2023
Kumar V, Hertz M, Agro A, Byrne AJ.
europepmc   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma. [PDF]

Exp Hematol Oncol
Li YR, DiBernardo GA, Chen Y, Shen X, Hon R, Ruegg LE, Huang J, Neal A, Moatamed NA, Memarzadeh S, Yang L.   +10 more
europepmc   +1 more source

SPLENIC INVARIANT NATURAL KILLER T CELLS PLAY A SIGNIFICANT ROLE IN THE RESPONSE TO POLYMICROBIAL SEPSIS. [PDF]

Shock, 2023
Heffernan DS, Chung CS, Ayala A.
europepmc   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. [PDF]

Mol Ther
Barragán Bravo GA, de la Cerda DA, Landoni E, Dholakia K, Humeniuk P, Caraballo Galva LD, Wang Y, Tian G, Yang B, Guo L, Wood MS, Rios X, Xu X, Courtney AN, Di Pierro EJ, Jacob J, Li YH, Adaikkalavan A, Watanabe N, Mao S, Miles G, Dotti G, Metelitsa LS.   +22 more
europepmc   +1 more source

CD1d-Dependent Natural Killer T Cells Mediate Hypertension and Vascular Injury Through Interleukin-17A. [PDF]

J Am Heart Assoc, 2023
Xiao X, Hou CL, Zhang YL, Yang H, Wang XX, Wang HX.   +5 more
europepmc   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi   +8 more
wiley   +1 more source

<i>In vivo</i> stimulation of natural killer T cells and downstream regulatory T cells to reduce acute graft-versus-host disease. [PDF]

Ann Transl Med
Sluyter R, McErlean G.
europepmc   +1 more source